Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16
Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.
A research team that studies companies thinks Xeris Biopharma is doing well and raised how much they think the stock is worth, from 12 dollars to 16 dollars per share. This tells you the team believes the company is moving in a good direction, so it is worth keeping an eye on their progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.